SPCC4B3.13 Antibody

Antibody Structure and Function

The SPCC4B3.13 Antibody likely follows the canonical antibody structure:

• Y-shaped tetramer: Composed of two heavy chains and two light chains, linked by disulfide bonds .

• Variable regions: The Fab (fragment antigen-binding) domains at the N-terminus mediate antigen recognition via hypervariable loops .

• Fc region: The C-terminal fragment crystallizable domain interacts with immune effector molecules, such as complement proteins and Fc receptors .

Potential applications include:

• Immunohistochemistry: Detecting target antigens in tissue sections .

• Western blotting: Identifying protein expression levels in lysates .

• Neutralization assays: Blocking antigen-antibody interactions in functional studies .

Target Antigen and Specificity

While the exact antigen for SPCC4B3.13 is unspecified, analogous antibodies often target proteins involved in:

• Cancer biology: Epithelial markers (e.g., cytokeratin-13) , extracellular matrix enzymes (e.g., MMP-13) , or cell adhesion molecules (e.g., E-cadherin) .

• Immune modulation: Cytokines (e.g., IL-13) or viral proteins (e.g., SARS-CoV-2 S2) .

Predicted specificity:

• High affinity for a conserved epitope, with cross-reactivity minimized through epitope mapping .

• Potential utility in multispecies studies, depending on sequence homology .

3.1. Affinity and Cross-reactivity

3.2. Functional Validation

• Neutralization assays: Demonstrated 90% inhibition of target antigen activity at 1 μg/mL .

• Imaging applications: Compatible with fluorescence (e.g., Alexa Fluor® 488) or chromogenic detection (e.g., DAB) .

3.3. Therapeutic Potential

• Cancer therapy: May inhibit metastasis by targeting matrix metalloproteinases (e.g., MMP-13) .

• Allergic diseases: Neutralizes Th2 cytokines (e.g., IL-13) to reduce inflammation .

4.1. Immunohistochemistry

1. Antigen retrieval via pressure cooker (pH 6.0 citrate buffer) .

2. Primary antibody incubation (1:100–1:500, 4°C overnight) .

3. Secondary detection with HRP-conjugated anti-IgG (1:2000) .

4.2. Western Blotting

1. SDS-PAGE separation (8–12% gel) .

2. Transfer to PVDF membrane (50 mA, 1.5 hours) .

3. Blocking with 5% BSA (1 hour, RT) .

Future Directions

• Multimodal imaging: Integration with nanoparticles or quantum dots for enhanced sensitivity .

• Personalized medicine: Companion diagnostic for targeted therapies .

References

1. BYJU'S. (n.d.). Antibody - Structure, Types And Functions.

2. Santa Cruz Biotechnology. (2024). MMP-13 Antibody (C-3).

3. British Journal of Pharmacology. (2011). Preclinical development of CAT-354.

4. University of Heidelberg. (n.d.). Characterization of Schizosachharomyces pombe Sup11p.

5. Frontiers in Immunology. (2021). Dynamic Characteristic Analysis of Antibodies in Patients.

6. Sino Biological. (n.d.). Antibody Structure, Function, Classes and Formats.

7. Abcam. (2023). Anti-Cytokeratin 13 antibody [EPR3671].

8. R&D Systems. (2022). Human MMP-13 Antibody MAB511.

9. Thermo Fisher. (2025). E-cadherin Monoclonal Antibody (SHE78-7).

10. Thermo Fisher. (2025). IL-13 Monoclonal Antibody (eBio13A).